|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luyten A, Scherbring S, Reinecke-Lüthge A,
Braun BE, Pietralla M, Theiler K and Petry KU: Risk-adapted primary
HPV cervical cancer screening project in Wolfsburg,
Germany-experience over 3 years. J Clin Virol. 46 Suppl 3:S5–S10.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moody CA and Laimins LA: Human
papillomavirus oncoproteins: Pathways to transformation. Nat Rev
Cancer. 10:550–560. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Knight T and Irving JA: Ras/Raf/MEK/ERK
pathway activation in childhood acute lymphoblastic leukemia and
its therapeutic targeting. Front Oncol. 4:1602014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Spaans VM, Trietsch MD, Crobach S, Stelloo
E, Kremer D, Osse EM, Haar NT, van Eijk R, Muller S, van Wezel T,
et al: Designing a high-throughput somatic mutation profiling panel
specifically for gynaecological cancers. PLoS One. 9:e934512014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Janku F, Lee JJ, Tsimberidou AM, Hong DS,
Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I and Kurzrock
R: PIK3CA mutations frequently coexist with RAS and BRAF mutations
in patients with advanced cancers. PLoS One. 6:e227692011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kotoula V, Sozopoulos E, Litsiou H,
Fanourakis G, Koletsa T, Voutsinas G, Tseleni-Balafouta S,
Mitsiades CS, Wellmann A and Mitsiades N: Mutational analysis of
the BRAF RAS and EGFR genes in human adrenocortical carcinomas.
Endocr Relat Cancer. 16:565–572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Holderfield M, Deuker MM, McCormick F and
McMahon M: Targeting RAF kinases for cancer therapy: BRAF-mutated
melanoma and beyond. Nat Rev Cancer. 14:455–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Su F, Viros A, Milagre C, Trunzer K,
Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT,
et al: RAS mutations in cutaneous squamous-cell carcinomas in
patients treated with BRAF inhibitors. N Engl J Med. 366:207–215.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jang S and Atkins MB: Which drug and when,
for patients with BRAF-mutant melanoma? Lancet Oncol. 14:e60–e69.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ojesina AI, Lichtenstein L, Freeman SS,
Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio
L, Cibulskis K, Bertelsen B, et al: Landscape of genomic
alterations in cervical carcinomas. Nature. 506:371–375. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zou Y, Zeng Y, Zhang DF, Zou SH, Cheng YF
and Yao YG: IDH1 and IDH2 mutations are frequent in Chinese
patients with acute myeloid leukemia but rare in other types of
hematological disorders. Biochem Biophys Res Commun. 402:378–383.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Platt AR, Woodhall RW and George AL Jr:
Improved DNA sequencing quality and efficiency using an optimized
fast cycle sequencing protocol. Biotechniques. 43:58–62. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ihle MA, Fassunke J, König K, Grünewald I,
Schlaak M, Kreuzberg N, Tietze L, Schildhaus HU, Büttner R and
Merkelbach-Bruse S: Comparison of high resolution melting analysis,
pyrosequencing, next generation sequencing and immunohistochemistry
to conventional Sanger sequencing for the detection of p.V600E and
non-p.V600E BRAF mutations. BMC Cancer. 14:132014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Monzon FA, Ogino S, Hammond ME, Halling
KC, Bloom KJ and Nikiforova MN: The role of KRAS mutation testing
in the management of patients with metastatic colorectal cancer.
Arch Pathol Lab Med. 133:1600–1606. 2009.PubMed/NCBI
|
|
17
|
Tsiatis AC, Norris-Kirby A, Rich RG, Hafez
MJ, Gocke CD, Eshleman JR and Murphy KM: Comparison of Sanger
sequencing, pyrosequencing, and melting curve analysis for the
detection of KRAS mutations: Diagnostic and clinical implications.
J Mol Diagn. 12:425–432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yao YG, Ogasawara Y, Kajigaya S, Molldrem
JJ, Falcão RP, Pintão MC, McCoy JP Jr, Rizzatti EG and Young NS:
Mitochondrial DNA sequence variation in single cells from leukemia
patients. Blood. 109:756–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yao YG, Kajigaya S and Young NS:
Mitochondrial DNA mutations in single human blood cells. Mutat Res.
779:68–77. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kang S, Kim HS, Seo SS, Park SY, Sidransky
D and Dong SM: Inverse correlation between RASSF1A
hypermethylation, KRAS and BRAF mutations in cervical
adenocarcinoma. Gynecol Oncol. 105:662–666. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wright AA, Howitt BE, Myers AP, Dahlberg
SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle
N, Jones RT, et al: Oncogenic mutations in cervical cancer: Genomic
differences between adenocarcinomas and squamous cell carcinomas of
the cervix. Cancer. 119:3776–3783. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chung TK, Van Hummelen P, Chan PK, Cheung
TH, Yim SF, Yu MY, Ducar MD, Thorner AR, MacConaill LE, Doran G, et
al: Genomic aberrations in cervical adenocarcinomas in Hong Kong
Chinese women. Int J Cancer. 137:776–783. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Samatar AA and Poulikakos PI: Targeting
RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug
Discov. 13:928–942. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte
G, Mazzarino MC, et al: Mutations and deregulation of
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy
response. Oncotarget. 3:954–987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pappa KI, Choleza M, Markaki S, Giannikaki
E, Kyroudi A, Vlachos G, Voulgaris Z and Anagnou NP: Consistent
absence of BRAF mutations in cervical and endometrial cancer
despite KRAS mutation status. Gynecol Oncol. 100:596–600. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iida K, Nakayama K, Rahman MT, Rahman M,
Ishikawa M, Katagiri A, Yeasmin S, Otsuki Y, Kobayashi H, Nakayama
S and Miyazaki K: EGFR gene amplification is related to adverse
clinical outcomes in cervical squamous cell carcinoma, making the
EGFR pathway a novel therapeutic targe. Br J Cancer. 105:420–427.
2011. View Article : Google Scholar : PubMed/NCBI
|
